Navigation Links
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Date:2/6/2009

idenix.com.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

Idenix Pharmaceuticals Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipate," "could," "may," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in HIV, or any potential pipeline candidates for the treatment of HIV, including any expressed or implied statement regarding the efficacy and safety of IDX899 and any future clinical trials involving IDX899. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre-clinical studies and/or clinical trials evaluating its product candidates, including IDX899; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; changes in the company's business pl
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... Global healthcare company GSK reports ... headwinds, increased price competition and supply disruptions to its ... points out that the company is very much in ... be confident about long-term prospects as well as the ... CFO Simon Dingemans adds that the company ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... SPRING, Md., June 20, 2011 The U.S. Food ... help advance the development and approval of an artificial ... United States. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... condition in which the pancreas produces little or no ...
... (NYSE Amex: CUR ) announced that it has ... Phase Ia trial to test the safety of NSI-189 for ... drug in healthy volunteers for safety and tolerability. NSI-189 is ... new neuron growth in the hippocampus, an area of the ...
Cached Medicine Technology:FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:7/23/2014)... combining salmon fibrin injections into the spinal cord and ... voluntary motor function impaired by spinal cord injury, scientists ... In a study on rodents, Gail Lewandowski and Oswald ... clock in a molecular pathway critical to the formation ... so that neuronal axons at the injury site could ...
(Date:7/23/2014)... 2014 This report defines and segments ... Europe, the Middle East & Africa, and Americas) - ... geography with analysis and forecasts of the global revenue. ... from over $10 billion in 2014 to nearly $14 ... , browse 49 Market Tables and 10 Figures ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug ... a great start and gives them a solid foundation ... new Internet Addiction section of its website at ... that Internet addiction is not just as legitimate a ... it’s trapping more and more victims each year – ...
(Date:7/23/2014)... -- Children and teens who lose a parent might face ... new study suggests. People who were children or teens ... of death during the study period than those who had ... report. Although the study found an association between a ... it wasn,t designed to prove cause-and-effect. Also, the increased ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... artists like Ram Kumar, V S Gaitonde and Jehangir ... of contemporary Indian paintings and sculptures held at Durban ... // ,Since having a cultural co-operation between Indian ... between the gallery like Iziko South African National Gallery ...
... painstaking and reaps benefits only when done with full dedication. ... in Georgetown. This has brought to the world the first cancer ... when on June 8, the Food and Drug Administration approved the ... of HPV. ,In the doctor’s own words, "It's a ...
... colleagues at the Indiana University Medical Center, Indianapolis say ... into having unwanted sex //. ,Unwanted sex ... researchers write in the June issue of the Archives ... result in risk for sexually transmitted infections and pregnancies. ...
... inputs on the manner of T-cells enabling immunity and furthering ... will go a long way in measuring the efficiency of ... ,Led by researchers at Beth Israel Deaconess Medical ... National Institute of Allergy and Infectious Diseases (NIAID), part of ...
... leader Sri Sri Ravishankar has said practising yoga, pranayam and ... alcohol abuse. // ,'Youths crave for something different ... dhyan (meditation) to them,' he said while interacting with reporters ... Kundaim, 15 km from here., ,Ravi Shankar appealed to ...
... that secondhand smoking can be deadly. Hence California and Washington laws ... was 58 years old physically fit suffered from heart problems that ... he worked in smoky taverns for 37 years. So the doctors ... to find that the indoor air pollution levels in bars that ...
Cached Medicine News:Health News:Research on AIDS vaccine a wealth of information 2Health News:Research on AIDS vaccine a wealth of information 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: